Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators

EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.